Megna, M.; Ruggiero, A.; Battista, T.; Marano, L.; Cacciapuoti, S.; Potestio, L.
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study. J. Clin. Med. 2023, 12, 3233.
https://doi.org/10.3390/jcm12093233
AMA Style
Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L.
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study. Journal of Clinical Medicine. 2023; 12(9):3233.
https://doi.org/10.3390/jcm12093233
Chicago/Turabian Style
Megna, Matteo, Angelo Ruggiero, Teresa Battista, Laura Marano, Sara Cacciapuoti, and Luca Potestio.
2023. "Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study" Journal of Clinical Medicine 12, no. 9: 3233.
https://doi.org/10.3390/jcm12093233
APA Style
Megna, M., Ruggiero, A., Battista, T., Marano, L., Cacciapuoti, S., & Potestio, L.
(2023). Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study. Journal of Clinical Medicine, 12(9), 3233.
https://doi.org/10.3390/jcm12093233
